[A23-101] Brolucizumab (neovascular age-related macular degeneration) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Last updated 02.05.2024
Project no.:
A23-101
Commission:
Commission awarded on 20.10.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Adults with neovascular (wet) age-related macular degeneration
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A23-101
| Project no. | Title | Status |
|---|---|---|
| A22-50 | Brolucizumab (visual impairment due to diabetic macular oedema) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-23 | Brolucizumab (neovascular age-related macular degeneration) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-31 | Brolucizumab (neovascular age-related macular degeneration) – Addendum to Project A23-101 | Commission completed |
Federal Joint Committee (G-BA)
2024-05-02 A G-BA decision was published.